1. The advent of monoclonal antibodies in the treatment of chronic autoimmune diseases

   • Valeria Bruno
   • Giuseppe Battaglia
   • Ferdinando Nicoletti

   Opening Lecture 20 July 2010 Pages: 283 - 288

   

2. Swedish natalizumab (Tysabri) multiple sclerosis surveillance study

   • Fredrik Piehl
   • C. Holmén
   • T. Olsson

   Session I – Natalizumab: International Experience 16 June 2010 Pages: 289 - 293

3. Three years of experience: the Italian registry and safety data update

   • G. L. Mancardi
   • G. Tedeschi
   • L. Provinciali

   Session I – Natalizumab: International Experience 20 July 2010 Pages: 295 - 297

4. Efficacy and tolerability of natalizumab in relapsing–remitting multiple sclerosis patients: a post-marketing observational study

   • F. Sangalli
   • L. Moiola
   • G. Comi

   Session II- Natalizumab: Italian Experience 11 June 2010 Pages: 299 - 302

   

5. Natalizumab treatment in multiple sclerosis: the experience of S. Andrea MS Centre in Rome

   • L. Prosperini
   • G. Borriello
   • Carlo Pozzilli

   Session II – Natalizumab: Italian Experience 10 June 2010 Pages: 303 - 307

   

6. The cohort of the multiple sclerosis center of Cagliari

   • M. G. Marrosu
   • L. Lorefice
   • E. Cocco

   Session II – Natalizumab: Italian Experience 26 January 2011 Pages: 309 - 312

   

7. Natalizumab: state of the art and open questions

   • G. Comi

   Session II – Natalizumab: Italian Experience 24 November 2010 Pages: 313 - 315

   

8. Natalizumab prevents the accumulation of cortical lesions in relapsing remitting multiple sclerosis: a preliminary report

   • F. Rinaldi
   • M. Calabrese
   • P. Gallo

   Session III – Natalizumab: Update on New Clinical and Radiological Evidence 10 June 2010 Pages: 317 - 320

9. Natalizumab efficacy on cognitive impairment in MS

   • F. Mattioli
   • C. Stampatori
   • R. Capra

   Session III – Natalizumab: Update on New Clinical and Radiological Evidence 10 June 2010 Pages: 321 - 323

10. Improvement of visual acuity in patients with severe visual loss affected by multiple sclerosis treated with natalizumab: a case report

    • Ciro Florio
    • Giorgia Teresa Maniscalco

    Session III – Natalizumab: Update on New Clinical and Radiological Evidence 02 July 2010 Pages: 325 - 327